Effect of inhalation of thermal water on airway inflammation in chronic obstructive pulmonary disease  by Pellegrini, Manuela et al.
ARTICLE IN PRESSRespiratory Medicine (2005) 99, 748–754KEYWORD
Lung funct
Cytology;
Induced sp
Leucocyte
Smoking;
Quality of
0954-6111/$ - s
doi:10.1016/j.r
Correspondi
E-mail addrEffect of inhalation of thermal water on
airway inflammation in chronic obstructive
pulmonary disease
Manuela Pellegrinia, Davide Fanina, Yohann Nowickia,
Gabriella Guarnieria, Anna Bordina, Diego Faggianb,
Mario Plebanib, Marina Saettac, Piero Maestrellia,aDepartment of Environmental Medicine and Public Health, University of Padova, via Giustiniani,
2 35128 Padova (PD), Italy
bDepartment of Laboratory Medicine, University Hospital, Padova
cDepartment of Clinical and Experimental Medicine, University of Padova, Italy
Received 14 May 2004S
ion;
utum;
s;
life
ee front matter & 2004
med.2004.11.001
ng author. Tel.: +39 049
ess: piero.maestrelli@uSummary Thermal water inhalations have been traditionally used in the
treatment of upper and lower chronic airway diseases. However, the benefit and
the mechanism of this treatment have not been properly assessed.
To determine whether inhaled salt-bromide-iodine thermal water improves lung
function, quality of life and airway inflammation, 39 patients with chronic
obstructive pulmonary disease (COPD) were randomly assigned to receive 2-weeks
inhalation treatment with thermal water (active, no. ¼ 20) or normal saline
(control, no. ¼ 19) in single blind.
Lung volumes were measured, Saint George’s respiratory questionnaire (SGRQ)
was administered and induced sputum was performed before and after treat-
ment.
No changes in pre- and post-salbutamol lung volumes was observed after
inhalation treatment in both groups. SGRQ score showed a significant improvement
in active group compared with control group at the end of the trial. The
concentration of total cells in induced sputum increased significantly in both active
(Po0:05) and control groups (Po0:05). Inhalation of thermal water induced a small
but significant decrease in percentages of sputum neutrophils (Po0:01) and a
parallel increase in macrophages (Po0:01). In contrast, normal saline inhalation was
not associated with changes in differential sputum cell counts.
In conclusion, treatment with inhaled salt-bromide-iodine thermal water in COPD
is associated with a reduced proportion of neutrophils in induced sputum suggestingElsevier Ltd. All rights reserved.
821 2564; fax: +39 049 821 2566.
nipd.it (P. Maestrelli).
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However, the short-term improvement in some components health-related quality of
life was not related with changes in lung function or with the degree of airway
inflammation.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is
clinically characterised by progressive airflow limita-
tion often associated with excessive sputum produc-
tion.1,2 The inflammatory process implicated in COPD
are detectable in different compartment of the
airways and lung parenchyma.3–7 Current treatment
modalities for COPD are limited. These include
symptom relief by bronchodilators. In addition, the
appreciation that COPD is an inflammatory condition
has led to manage the disease with agents that
suppress the inflammation.2 Inhalation of thermal
water has been used empirically in the treatment of
chronic diseases of upper and lower respiratory tract,
including COPD. The benefit of thermal water has
been attributed, at least partially, to its anti-
inflammatory properties.8,9 However, the type and
degree of this activity on the airways of patients with
COPD has not been performed by controlled studies.
Analysis of induced sputum is a minimally invasive
technique which has been used to directly evaluate
airway inflammation in several clinical trials in
COPD.10 We specifically investigated whether a
conventional course of inhaled salt-bromide-iodine
thermal water would modify airway inflammation in
patients with COPD treated for 2 weeks in a parallel-
group randomized, placebo controlled study. Induced
sputum was obtained from patients before and after
treatment. Inflammatory cells and concentration of
inflammatory mediators were examined in induced
sputum. In addition, measurement of lung function,
dyspnea and exercise tolerance, and health-related
quality of life were performed.Methods
Subjects and design of the study
We recruited 39 patients with stable COPD (35 men
and 4 women, aged 44–76 years) from the out-
patient department of University Hospital, Padova,
and a local general practice. Inclusion criteria for
entry were a smoking history of at least 10 pack-
year, chronic bronchitis (a cough with excess of
sputum production for at least 3 months in at least
2 consecutive years without any other disease)1 orFEV1/FVCo70%, and reversibility with inhaled
salbutamol of o15% or 200ml of initial FEV1.2
Patients with a history of asthma or atopy, or with
other clinically significant diseases, and patients
who had suffered a respiratory tract infection or
exacerbation of their disease or had taken inhaled
or systemic corticosteroids in the previous month
were excluded. All subjects gave written informed
consent, and the study was approved by the ethics
committee of the University Hospital of Padova.
The patients were randomly assigned to receive
2-weeks inhalation treatment with thermal water
(active group, no. ¼ 20) or normal saline (control
group, no. ¼ 19) in single blind. Thermal water
originated from hot springs (approximately 80 1C) in
the Terme Euganee area (Abano-Montegrotto,
Veneto, Italy). The main solutes in the water are
Br (13.6 g/l), Cl (2.2 g/l), Na (1.2 g/l), SO4 (1.0 g/l),
I (0.8 g/l), Ca (0.4 g/l). Thermal water was free
from bacterial contamination, had a pH ¼ 7.1 and
osmolarity of 124mmol/l.
Thermal water or sterile normal saline solution
were warmed up at a temperature of approxi-
mately 37 1C and nebulised. The aerosols were
administered once a day for 20min. Each subject
was examined twice, before and after the 2-weeks
treatment. Each visit included the evaluation of
health-related quality of life using the Italian
version of the St. George’s respiratory question-
naire (SGRQ),11 pulmonary function tests, a 6-min
walking test and sputum induction.
Pulmonary function tests
Pulmonary function tests were performed with a
spirometer (Biomedin, Padova, Italy) as previously
described12 and included the measurements of FEV1
and FVC before and 15min after inhalation of
200 mg of salbutamol. Subjects were tested at least
12 h after the last inhaled bronchodilator. The
predicted normal values were those from Commu-
nite` Europe`enne du Carbon e de l’Acier (CECA).13
Six minutes walking test
Subjects were instructed to walk as far as they
could for 6min along a 32m corridor.14 Before and
after the test arterial oxygen saturation and heart
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(Onyx 9500 Oximeter, Nonin Medical Inc., Minnea-
polis, USA). Walk distance in meters and dispnea
according to Borg scale were evaluated at the end
of the test.
Sputum induction and analysis
Sputum was induced by inhalation of hypertonic
saline as described.12 Briefly, FEV1 was measured
before and 10min after salbutamol inhalation
(200 mg). Hypertonic saline was nebulised with an
ultrasonic nebuliser (Ultra Neb 2000, De Vilbiss
Health Care, Somerset, PA, USA) for 5min periods,
up to 20min. The concentration of saline was
increased at intervals of 10min from 3% to 4%. Each
5min subjects were asked to rinse their mouths and
throats and then invited to cough sputum into a
Petri dish. Sputum plugs arising from the lower
respiratory tract were selected and gently mixed
with dithiothreithol 0.1% (Sputasol; Oxoid Ltd.,
Basingstoke, England). The supernatant was sepa-
rated and aliquots were kept frozen at 80 1C until
analysed. The cell suspension was spun in a
cytocentrifuge (Shandon Cytospin2; Shandon, Oak-
land, CA), and the slides were stained with Diff
Quick for differential cell counts of leukocytes and
squamous epithelial cells. The slides were coded
and 400 cells were counted blindly for differential
leukocyte count. A sample was considered ade-
quate when the percentage of squamous cells was
lower than 20%. To correct for the variable salivary
contamination, the results of differential leuko-
cytes counts were expressed as a percentage of
nucleated cells excluding squamous cells.
Myeloperoxidase (MPO) concentrations in sputum
supernatant were determined with a commercially
available radioimmunoassay (Pharmacia Diagnostics
AB, Uppsala, Sweden) according to the manufac-
turer’s instructions.Table 1 Baseline characteristics of patients in each trea
Sex (M/F)
Age (yr)
Smoking history (pack-yr)
FEV1 (% predicted)
FEV1/FVC%
Post-bronchodilator FEV1 (% baseline)
Arterial oxygen saturation (%)
Dyspnea score (Borg scale)
Data are expressed as mean7SE.Eosinophils cationic protein (ECP) concentrations
were measured using anti-ECP monoclonal antibody
coupled to ImmunoCAP according to the manufac-
turer’s instructions (Pharmacia Diagnostics).
Data analysis
Group data were expressed as means7standard
error or median and interquartile ranges. The
comparison of the results was made using Man-
n–Whitney U test or the Wilcoxon’s rank sum test.
The relationship between sputum cytology results
and SGRQ scores was evaluated with the Spearman
rank correlation test. The significance was ac-
cepted at the 5% level.Results
The baseline characteristics of the patients are
shown in Table 1. According to the GOLD classifica-
tion of severity 16 patients were at stage 0, 9 at
stage I, 3 at stage II, 10 at stage III, and 1 at stage
IV.2 The two groups were similar with regard to age,
sex, smoking history, pulmonary function tests and
overall severity of the disease. No COPD exacerba-
tion occurred during the course of the study and
inhaled treatments were well tolerated.
A significant reduction of the SGRQ total score
was observed after thermal water treatment
indicating an improvement of health related
quality of life (Table 2). The improvement in active
group regarded the Activity and Impact sections. In
contrast, no changes in SGRQ scores was detected
in control group.
There was no significant change in lung function
indices after control or thermal water treatment
periods. Similarly, no differences were detected
in walk distance, post-exercise arterial oxygen
saturation and dyspnea score measured during thetment group.
Control Thermal water
(n ¼ 19) (n ¼ 20)
16/3 19/1
6572 6372
3373 3574
7176 7375
6272 6973
671 571
9570.4 9570.4
0.770.1 0.770.1
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Table 2 Changes in health-related quality of life assessed by St. George’s respiratory questionnaire before and
after treatment with inhaled normal saline (control) and thermal water.
SGRQ score Control Thermal water
Baseline After treatment Baseline After treatment
Symptoms (1–100) 4175 4375 3674 3274
Activity (1–100) 4475 4875 4074 2974*
Impact (1–100) 2674 3374 1874 1473*
Total score (1–100) 3473 3874 2873 2273*
Data are expressed as mean7SE.
*Po0.01 compared with corresponding values in control group (Mann–Whitney test).
Thermal water in COPD 7516-min walk test. The proportion of patients who
increased the walking distance of more than 30m
was higher in active treatment (n ¼ 8; 40%) than in
control (n ¼ 4; 21%), but the difference was not
statistically significant. Subgroup analysis per-
formed excluding the subjects with FEV1/
FVC470% did not show significant differences in
FEV1 (change after treatment: thermal water
1.671.6%; control 0.771.3%) or walk distance
(change after treatment: thermal water
22720m; control 1377m) in subjects with mild
to severe COPD.
The induction of sputum was well tolerated and
all patients produced adequate samples. The
amount of sputum plugs collected before treat-
ment was similar in the two groups (control median
210mg [interquartile range 132–246]; thermal
water 216mg [139–276]) and did not change from
baseline on control (240mg [136–262]) or active
(205 [160–286]) treatment. A significant increase in
the total cell number was observed in either groups
after treatment (Table 3).
The percentage of sputum neutrophils signifi-
cantly decreased after treatment with inhaled
thermal water compared with pre-treatment va-
lues, while the percentage of macrophages in-
creased. The observed changes were small, but
consistent among patients (Fig. 1). Differential cell
counts did not change from baseline on control
treatment (Table 3). Similarly, the concentrations
of MPO and ECP remained unchanged throughout
the study in both groups. No correlation was
detected between SGRQ and lung function or
sputum indices.Discussion
This is the first controlled study to examine the effect
of a standard course of inhaled salt-bromide-iodinethermal water on respiratory function and airway
inflammation in COPD. We showed that the active
treatment was associated with a short-term improve-
ment in health-related quality of life without changes
in lung volumes, arterial oxygen saturation or
exercise capacity. The reduction in the proportion
of sputum neutrophils detected at the end of the
course of thermal water inhalation might be regarded
as a mild anti-inflammatory effect of salt-bromide-
iodine thermal water on the airways in COPD.
However, it appears insufficient to explain the
benefit of thermal water on health status perception.
Larger studies may be necessary to confirm these
observations.
COPD is characterised by airflow limitation. Some
components of the functional impairment may be
partially reversible.2 It was hypothesised that
thermal water could act on these components by
reducing inflammation and/or modifying mucous
properties. Reduction of mucus in the lumen of the
airways or of inflammatory infiltrate in the airway
wall would result in higher expiratory flows.
Improved accessibility of inhaled drugs to airway
smooth muscle would increase post-bronchodilator
FEV1. Finally, better lung distribution of ventilation
would improve exercise capacity of the subjects.
None of these effects had been demonstrated in
our study. The inclusion in the trial of patients with
insufficiently severe disease might have prevented
the detection of treatment effects on lung func-
tion. Subgroup analysis performed excluding the
subjects at risk (stage 0) according to GOLD
classification, apparently did not confirm this
hypothesis, since no different outcome was ob-
served in subjects with mild to severe COPD.
However, we need to be cautious with this
interpretation, since the lower number of subjects
in subgroups reduces the power of statistics.
Different individual response to treatment is a
common problem in clinical trials. A cross-over
design of the study could have reduced the
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Table 3 Inflammatory indices in induced sputum before and after treatment with inhaled normal saline
(control) and thermal water.
Induced sputum Control Thermal water
Baseline After treatment Baseline After treatment
Total cell count/mg (no.) 1776 2700* 2881 2964*
(1104–2591) (2161–3958) (1655–4786) (1944–9218)
Viability (%) 92 91 92 90
(89–98) (88–94) (90–94) (85–95)
Differential cell count
Macrophages (%) 38.2 35.5 34.1 37.6*
(27–52) (26–54) (22–49) (29–52)
Neutrophils (%) 61.6 65.1 64.3 61.8*
(48–72) (55–77) (50–78) (47–71)
Eosinophils (%) 0.3 0.0 0.3 0.3
(0.1–0.8) (0.0–0.8) (0.0–0.2) (0.0–0.0)
Lymphocytes (%) 0.0 0.0 0.0 0.0
(0.0–0.2) (0.0–0.1) (0.0–0.4) (0.0–0.1)
Sputum supernatant
MPO (ng/ml) 194 217 200 233
(89–380) (20–522) (46–335) (39–555)
ECP (ng/ml) 95 80 59 57
(61–200) (54–200) (27–150) (20–131)
Data are expressed as median (interquartile range).
*Po0.01 compared with corresponding baseline values (Wilcoxon signed rank test). MPO ¼ myeloperoxidase;
ECP ¼ eosinophil cationic protein.
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Figure 1 Individual percentages of sputum neutrophils before and after treatment with inhaled thermal water and
normal saline (control).
M. Pellegrini et al.752influence of individual variability. However, we
chose a parallel group study design because it is
unknown if there is any carry over effect of
inhalations.
The hypothesis that thermal water had anti-
inflammatory properties was based on few previous
studies performed in patients with rhinitis. Treat-
ment with sulphurous thermal water resulted in
a reduction of polymorphonuclar cells in nasalcytology of patients with chronic inflammation of
upper respiratory tract.8 Improvement of symp-
toms, decrease in serum IgE and increase in serum
IgA was observed in patients with perennial allergic
rhinitis after treatment with iodine bromide ther-
mal water.9 However, no investigations were
performed in lower respiratory tract. The decrease
in sputum neutrophils is consistent with the
observation made in nasal cytology after inhalation
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predominant feature of intraluminal airway inflam-
mation in COPD15–17 and percentages of sputum
neutrophils correlated with accelerated decline of
FEV1 over 15 years.
5 For these reasons treatments
aimed to reduce airway neutrophilia should be
regarded as beneficial. Most of current treatment
modalities for COPD have no or controversial
effects on the inflammatory process. Two studies
in patients with COPD have reported a reduction in
sputum neutrophils after inhaled corticoster-
oids,18,19 but these results were at variance of
further reports.20,21 A reduction in sputum neutro-
phils has been demonstrated after treatment with
theophylline,22 but a trial with a more specific
phosphodiesterase-4 inhibitor failed to show
changes in sputum inflammatory cells.23 The
neutrophil decrease detected after inhaled thermal
water was consistently homogeneous. However, the
size of neutrophil reduction was minimal and at the
end of the trial the subjects retained their
characteristic neutrophilic inflammation. Since
our study was designed to investigate the effects
of conventional course of inhaled thermal water, it
cannot be ruled out that higher doses or more
prolonged periods of treatment might be applied to
obtain more relevant results.
The increased recovery of cells in induced
sputum observed after both treatments is consis-
tent with the observations made in COPD patients
that inhalation of isotonic or hypertonic solutions
administered by nebulisation induce increase in
airway secretion that can be expectorated.24,25 The
mechanisms by which this occur are not known26
and the present study was not designed for
mechanistic investigation. Inflammatory mediator
release has been shown after exposure of human
airways to hyperosmolar solutions.27 In contrast,
we did not observe any alteration of the secretory
profile of sputum granulocytes. Previous reports
have demonstrated increased clearance of secre-
tions from the airways in humans after administra-
tion of hypertonic saline aerosols.28 However, since
the increase in sputum leucocytes was irrespective
of the type of solution administered to our
patients, our findings suggest that the amount of
fluid deposited the airways favours the recovery of
cells rather than the properties of the solutes.
Indeed, hydration has been used empirically in
chest physical therapy, and there is some objective
evidence in animal model that hydration increase
tracheal mucus transport velocity.29
The SGRQ resulted a sensitive method to detect
changes in health status of our COPD patients.
We provide evidence of some benefit of a course
of inhalation of thermal water in COPD. Activetreatment significantly improved the activity and
impact domains, but not symptoms. This is in line
with the lack of functional changes detected in the
patients. Otherwise, it is not clear which effect of
thermal water is responsible of such improvement
since no correlation was detected with question-
naire scores or indices of pulmonary function or
airway inflammation. One possible explanation of
the positive effect on quality of life could be that
some patients recognised the inhalation of thermal
water due to a different taste. Unblinded patients
could have been influenced by the common opinion
on the efficacy of thermal water to give more
favourable answers in the activity and impact
domains of SGRQ.
In summary, we have shown that treatment with
inhaled salt-bromide-iodine thermal water in COPD
is associated with a reduced proportion of neutro-
phils in induced sputum suggesting that thermal
water may have a mild anti-inflammatory effect on
the airways. However, the short-term improvement
in some components health-related quality of life
was not related with changes in lung function or
with the degree of airway inflammation. Thermal
water is not considered in the treatment of COPD
suggested by the most recent guidelines.2 Our data
do not provide sufficient evidence that a short
course of inhaled thermal water in COPD patients
has clinically relevant benefit to be included in the
standard management of COPD.Acknowledgements
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